pharma · Cystic Fibrosis · Hepatitis C
Vertex Pharmaceuticals (Australia)
Vertex Pharmaceuticals (Australia) Pty.
Vertex Pharmaceuticals (Australia) is a pharma organization headquartered in Boston, USA. Primary therapeutic focus areas include Cystic Fibrosis, Hepatitis C, Pain, Chronic Hepatitis C, Acute Pain. NovaPharmaNews links
Vertex Pharmaceuticals Inc., 50 Northern Avenue, Boston, MA 02210, US HQ
1989 Founded
6,304 Employees
TGA registrant Type
Company details
- Status
- Public
- HQ
- Vertex Pharmaceuticals Inc., 50 Northern Avenue, Boston, MA 02210, US
- Founded
- 1989
- Employees
- 6,304
- Programs
- 159
- Drugs
- 64
- Patents
- 991
VX-840
Phase 1 · small molecule · APOL1-mediated Kidney Disease
VX-840 for APOL1-mediated Kidney Disease is a Phase 1 program (small_molecule) at Vertex Pharmaceuticals (Australia) Pty. with 1 ClinicalTrials.gov record(s).
Internal code VX21-840-001
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Vertex Pharmaceuticals (Australia) Pty.
- Phase
- Phase 1
- Modality
- small_molecule
- Indication
- APOL1-mediated Kidney Disease
- Status
- completed
- Trials
- 1